Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients (2012)
- Authors:
- USP affiliated authors: ANDRADE, JURANDYR MOREIRA DE - FMRP ; TIÉZZI, DANIEL GUIMARÃES - FMRP ; PERIA, FERNANDA MARIS - FMRP
- Unidade: FMRP
- DOI: 10.1007/s12032-010-9793-8
- Subjects: ESTUDOS RETROSPECTIVOS; NEOPLASIAS MAMÁRIAS; QUIMIOTERAPIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Medical Oncology
- ISSN: 1357-0560
- Volume/Número/Paginação/Ano: v. 29, n. 1, p. 33-38, 2012
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
BRITO, Luiz Gustavo Oliveira et al. Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients. Medical Oncology, v. 29, n. 1, p. 33-38, 2012Tradução . . Disponível em: https://doi.org/10.1007/s12032-010-9793-8. Acesso em: 07 maio 2026. -
APA
Brito, L. G. O., Andrade, J. M. de, Lins-Almeida, T., Zola, F. E., Pinheiro, M. N., Marana, H. R. C., et al. (2012). Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients. Medical Oncology, 29( 1), 33-38. doi:10.1007/s12032-010-9793-8 -
NLM
Brito LGO, Andrade JM de, Lins-Almeida T, Zola FE, Pinheiro MN, Marana HRC, Tiezzi DG, Peria FM. Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients [Internet]. Medical Oncology. 2012 ; 29( 1): 33-38.[citado 2026 maio 07 ] Available from: https://doi.org/10.1007/s12032-010-9793-8 -
Vancouver
Brito LGO, Andrade JM de, Lins-Almeida T, Zola FE, Pinheiro MN, Marana HRC, Tiezzi DG, Peria FM. Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients [Internet]. Medical Oncology. 2012 ; 29( 1): 33-38.[citado 2026 maio 07 ] Available from: https://doi.org/10.1007/s12032-010-9793-8 - Breast conserving surgery after neoadjuvant therapy for large primary breast cancer
- Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab
- Recurrence and survival after neoadjuvant chemotherapy for locally advanced cervical cancer is dependent on the pathological response
- Expression of hypoxia-inducible factor 1-'alfa' and vascular endothelial growth factor-C in locally advanced breast cancer patients
- Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer
- Mouse renal 4T1 cell engraftment as a model to study the influence of hypoxia in breast cancer progression
- Volume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy
- Trastuzumab-induced myocardiotoxicity mimicking acute coronary syndrome
- Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer
- Genetic profile analysis of tumor stem cells in locally advanced breast cancer
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
